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Introduction
Atrial fibrillation (AF) is the most common sustained
arrhythmia, and its prevalence significantly increases
with age1,2. The odds ratio for AF for each decade of
advancing age is 2.1 for men and 2.2 for women3.
Overall, 70% of all patients with AF are ≥65 years old.
AF is associated with coronary artery disease, hyper-
tension, rheumatic heart disease, cardiomyopathy,
atrial septal defect, and sick sinus syndrome, and all of
these comorbid diseases are more prevalent in elderly
patients. Noncardiac disorders in elderly patients com-
monly associated with AF include pulmonary disease,
alcoholism, and hyperthyroidism.
Molecular Pathogenesis of AF
Morphologic changes in the atrial myocardium associ-
ated with AF may result from underlying cardiovascu-
lar disease and/or physiologic aging processes. The
autonomic innervations of the atrial myocardium and
the function of sinus node and atrioventricular node
may change because of the aging process. Underlying
molecular pathogeneses of AF include hypertrophy of
the atrial myocardium, vascular changes of sinus and
atrioventricular nodes, degenerative changes in the
atrial conduction system and the atrial myocardium,
acute and chronic inflammatory changes with necrosis,
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cellular infiltration, fatty metamorphosis, fibrosis, and
calcification.
The morphologic changes in the atrial myocar-
dium may lead to electrophysiologic abnormalities that
result in the mechanisms responsible for the occur-
rence of AF4. The presence of fibrosis or degenerative
changes may increase with old age; these molecular
and electrophysiologic changes may increase aniso-
tropic conduction and result in reentrant excitation. Fur-
thermore, the electrophysiologic or structural changes
in the atrial myocardium result from AF itself can in-
crease the potential for AF, supporting the concept that
AF begets AF5,6. The longer the duration of a paroxys-
mal episode, the greater the chance that the AF
episode will be sustained; finally, AF becomes chronic.
Complications of AF
Complications of AF are more common in elderly
patients. The sudden onset of paroxysmal AF may result
in exacerbation of congestive heart failure in some
patients, especially in those with aortic stenosis, coro-
nary artery disease, and hypertension. Permanent AF
with an uncontrolled rapid ventricular response may
result in tachycardia-induced cardiomyopathy. The
incidence of thromboembolic events significantly in-
creases in elderly patients with permanent AF. Risk
factors include previous transient ischemic stroke, hy-
pertension, left ventricular systolic dysfunction, dia-
betes mellitus, and coronary artery disease. AF is
responsible for 15% to 20% of all ischemic strokes, and
it is the most important cause of ischemic stroke in
the elderly.
Pharmacologic Therapy of AF
It is important to assess any comorbidity and potential
triggers of AF before considering pharmacologic ther-
apy for AF. Electrolyte disturbance, sepsis, hyperthy-
roidism, pulmonary disease, hypoxia, myocardial
ischemia, and left ventricular dysfunction may all trig-
ger a new episode of AF in elderly patients. The same
insults can also exacerbate the ventricular rate of AF in
patients with previously well-controlled ventricular
rate. Treating underlying problems will facilitate further
management, including rate control and rhythm con-
trol. The pharmacologic therapy of the patient with AF
includes three major considerations: (1) rate control,
(2) conversion and maintenance of sinus rhythm, and
(3) anticoagulation.
Rate control
Proper rate control should include control in response
to exercise, together with an avoidance of bradycar-
dias and symptomatic pauses in the patients with AF.
Digoxin, β-blockers and calcium channel blockers can
all be effective in controlling ventricular rate in the
elderly patients with AF. The β-blockers or calcium
channel blockers should be used in patients with
acute left ventricular failure and AF in whom the heart
failure is caused by the tachycardia. However, it is dan-
gerous to prescribe β-blockers and calcium channel
blockers in patients with AF and acute congestive
heart failure, in whom heart failure is not caused by
the tachycardia. The safest approach is to use small,
incremental doses of short-acting forms and reassess
frequently. On the other hand, digoxin appears rela-
tively safe in the patients with impaired left ventricular
function7,8.
Digoxin is a muscarinic agonist and limits conduc-
tion via the atrioventricular node at rest, but this effect
is limited during periods of high adrenergic drive.
Thus, digoxin is usually not effective in preventing an
acceleration of ventricular rate with physical activity
or in acute illness in elderly patients with AF. Digoxin is
well tolerated within the therapeutic range, and proper
digoxin serum level is often achieved with smaller doses
in elderly patients. Outside the therapeutic range,
digoxin toxicity is a common and potentially serious
complication. Combination therapy of digoxin with 
β-blockers or calcium channel blockers may be useful in
controlling ventricular rates in some elderly patients
with AF. Digoxin toxicity could be avoided in the 
combination therapy, because lower digoxin dosage is
required.
The use of β-blockers may be effective in control-
ling ventricular rate without producing extreme bra-
dycardia in some elderly patients with AF. Thus, they
can be used as first-line therapy for rate control in eld-
erly patients with AF. Numerous studies support the
safety and efficacy of their use alone and in combina-
tion with digoxin7,9. β-blocker may be effective in main-
taining sinus rhythm in patients with paroxysmal AF in
whom an adrenergic trigger is identified. β-blockers
are indicated in patients with ischemic heart disease,
stable left ventricular dysfunction, and hypertension.
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Their major limitation is that they cannot be used in
patients with bronchospasm and bradycardia.
A rate-slowing calcium channel blocker may be 
a useful alternative to control the ventricular rate in
patients with both AF and airway disease. Numerous
studies have demonstrated that both verapamil and
diltiazem are effective in controlling the ventricular
rate of AF in patients with physical activity. Unlike 
β-blockers, they do not decrease exercise tolerance,
but neither do they have prognostic benefit if chronic
heart failure persists. Previous studies suggested that
verapamil might prevent the recurrence of AF after
cardioversion by reducing intracellular calcium over-
load and AF-induced electrical remodeling. From the
viewpoint of electrical remodeling, verapamil may be
a better choice than digoxin for rate control10. Because
diltiazem and verapamil also have negative inotropic
effects, the use of incremental doses of short-acting
preparations is recommended.
In some elderly patients with AF, rapid ventricular
rate cannot be controlled with drug therapy, and these
patients need atrioventricular junction radiofrequency
ablation and implantation of permanent pacemak-
ers11,12. These therapies have been shown to be effec-
tive in controlling ventricular rate, reducing symptoms,
and improving quality of life. Tachycardia-bradycardia
syndrome is also a common problem when attempt-
ing to slow ventricular rate with drug therapy in eld-
erly patients with AF. The ventricular rate in such
patients alternates between too fast and too slow; AF
may be transient, and the underlying disorder may be
sick sinus syndrome in some patients. Such cases are
difficult to manage with drug therapy alone, and 
a pacemaker in addition to atrioventricular node-
blocking drugs is necessary to achieve good control of
the ventricular rate in these patients.
Rhythm control
The Atrial Fibrillation Follow-up Investigation of
Rhythm Management (AFFIRM) study compared phar-
macologic rhythm control with pharmacologic rate
control in predominantly older patients who had risk
factors for stroke, and the results showed no improve-
ment in quality of life, incidence of stroke, or mortal-
ity with a strategy of maintaining normal rhythm13,14.
Important limitations of the rhythm control strategy
in these trials included the limited ability of antiar-
rhythmic drugs to maintain sinus rhythm and the pos-
sible underutilization of anticoagulation in patients
assumed to be in sinus rhythm. However, in an AFFIRM
substudy, outcomes were improved in the subset of
patients in whom normal rhythm was maintained,
although it is unclear whether sinus rhythm was a direct
cause of the improved outcomes or a marker for other
factors associated with survival15. These studies sug-
gested that currently available antiarrhythmic drugs
are not associated with improved survival, and benefi-
cial antiarrhythmic effects of antiarrhythmic drugs may
be offset by their adverse effects. However, if an effec-
tive method for maintaining sinus rhythm with fewer
adverse effects were available, it might be beneficial
to elderly patients with AF.
Amiodarone blocks potassium channels and hence
prolongs the action potential duration. Amiodarone is
a complex drug that blocks potassium, sodium, cal-
cium channels, and β-receptors. Although torsades de
pointes and early idiosyncratic pulmonary toxicity
have been described, the majority of the more serious
side effects are related to substantial cumulative doses.
In clinical practice, doses as low as 50–100 mg are use-
ful to prevent paroxysmal AF or the recurrence of AF
after cardioversion. Amiodarone is safe in patients
with immediate post-myocardial infarction and left
ventricular failure16. In view of the high prevalence of
heart failure in elderly patients with AF and high
proarrhythmic effects of many antiarrhythmic drugs,
amiodarone has been suggested as the antiarrhythmic
drug of first choice in elderly patients with AF17. Amio-
darone is useful in preventing attacks in patients with
paroxysmal AF. Intravenous amiodarone can improve
cardioversion rates within the first 48 hours of onset.
Amiodarone also has a modest effect on rate control,
and this effect can be more pronounced in elderly
patients. Longer-term oral amiodarone will also
chemically cardiovert a small but significant number
of patients with chronic AF. Furthermore, it may
increase the chance of successful direct-current car-
dioversion and is effective in preventing subsequent
recurrence of AF18.
Propafenone is a sodium channel blocker that
modifies conduction rather than action potential dura-
tion. Propafenone has additional β-blocking activity,
and it is useful in preventing recurrence of AF after
cardioversion with limited follow-up. Propafenone is
useful in elderly patients with paroxysmal AF. However,
because propafenone has been shown to induce ven-
tricular tachycardias, great care should be taken when
prescribing propafenone to an elderly patient19.
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Anticoagulation
Old age has been shown to be an independent risk
factor for stroke in patients with AF. All patients of age
≥75 years should be considered as candidates for
chronic anticoagulant therapy. Multicenter random-
ized studies have shown that the use of long-term anti-
coagulation therapy significantly reduces the stroke
rate and the mortality rate in patients with AF20,21.
Despite its usefulness, warfarin therapy is fraught with
complications. The most important complication is
the risk of warfarin-induced hemorrhage, which also
increases with old age21–24. The risk of major bleeding
is known to increase with the presence of comorbid
illnesses such as hypertension, heart disease, renal
insufficiency, cancer, cerebrovascular disease, and
polypharmacy, and all of these comorbid illnesses are
more prevalent in elderly patients. Furthermore, some
elderly patients have gait disturbances with increased
fall risk, frailty, dementing illnesses, and logistical dif-
ficulties in assuring adequate monitoring of therapy.
Unfortunately, warfarin-induced bleeding is not rare.
The rate of major hemorrhage with warfarin use was
significantly higher in patients aged 75 years and older
than in younger patients (3.2% vs. 1.8% per patient-year)
despite identical targeted intensity of anticoagulation22.
Intracranial hemorrhage was also more frequent in
the older patients than the younger patients receiving
anticoagulation. Intracranial hemorrhage is especially
common in patients over the age of 85 years25. Because
most patients older than 75 years are female, warfarin-
induced hemorrhage is predominantly noted in women.
Thus, older patients and women usually require smaller
initiation and maintenance doses than younger or
male patients.
Numerous studies have demonstrated underuse of
warfarin among elderly patients who may benefit the
most from anticoagulant therapy. There was a 14%
reduction in warfarin use with each advancing decade
of life26. This association was independent of other
risk factors for stroke and for the defined bleeding-
associated contraindications to warfarin therapy. To
account for the possibility that warfarin exposure
occurred and was stopped because of hemorrhagic
complications before the study dates, further analysis
was restricted to subjects with no history of bleeding
contraindications. Even with this restricted analysis,
old age remained a significant deterrent to use of war-
farin. These findings have raised concerns regarding
quality of care, physician adherence to guidelines, and
translation of clinical trial results into real-world prac-
tice27,28. Physicians’ reluctance to treat older patients
with warfarin may be because of a perceived age-
related increase in bleeding complications. However,
some studies documented that warfarin therapy was
withheld more frequently in elderly patients than in
younger patients with identical elective indications.
Interestingly, a physician’s experience with bleeding
events associated with warfarin can influence their
prescription of warfarin. On the other hand, adverse
events that are possibly associated with underuse of
warfarin may not affect subsequent prescription29.
International normalized ratio (INR) levels of less
than 2.0 have been shown to be not effective in pre-
venting strokes in patients with AF, and levels greater
then 3.0 are associated with increased risk of bleed-
ing30. Furthermore, mortality, ischemic stroke and hos-
pitalization increased when INR was outside the target
range31. However, how prothrombin time is to be mon-
itored and the dose of warfarin be adjusted in patients
with AF still present a critical challenge in clinical prac-
tice. A centralized, telephonic, pharmacist-managed
system has been shown to improve therapeutic INR
control and reduce the risk of anticoagulation therapy-
related complications, when compared with the usual
anticoagulation therapy management provided by the
patient’s physician32. The clinical pharmacy anti-
coagulation service reduced the risk of experiencing 
a major bleeding, thromboembolic or fatal event while
receiving anticoagulant therapy by 39%, when com-
pared with usual care. Furthermore, home monitoring
of prothrombin time by the patient also appears to be
safe and effective, and it provides better results than
individual physician control of the INR33. A drop of
blood is obtained via finger prick, and a simple elec-
tronic device can determine the INR. The patient uses
a protocol supplied by the physician to determine the
dose of warfarin to be taken. However, careful patient
selection and education are vital to monitor prothrom-
bin time and adjust the dose of warfarin at home.
Conclusion
The first priority in managing elderly patients with AF
is identifying and correcting any precipitating and/
or exacerbating factors for AF. In parallel with this ap-
proach, effective rate control will often be achieved
using digoxin, β-blockers and/or calcium channel
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blockers. In the elderly, amiodarone is probably the
safest drug for short-term administration to exert
chemical cardioversion, facilitate electrical cardiover-
sion, and prevent recurrence of AF. However, doctors
should pay attention to the side effects of long-term
amiodarone therapy. Old age remains a significant
deterrent to the use of anticoagulant therapy in AF
patients. Better estimates of the risk associated with
anticoagulant use in the old patients are necessary for
optimal decision-making. Without these data, physi-
cians’ reluctance to use anticoagulation therapy in
elderly patients with AF will likely continue and may,
in fact, be warranted. On the other hand, some prom-
ising studies have shown that radiofrequency ablation
can eliminate AF in some old patients with an initiat-
ing focus, predominantly from the pulmonary veins34,35.
Radiofrequency ablation offers a potential cure of AF,
and it is particularly attractive for the elderly by spar-
ing them from long-term antiarrhythmic drug therapy
and anticoagulation.
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